COMMUNIQUÉS West-GlobeNewswire

Tetra Bio-Pharma Announces Record Date for Dividend-in-Kind of North Bud Farms Shares
31/08/2018
ORLEANS, Ontario, Aug. 31, 2018 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc . (" Tetra " or the " Corporation ") (TSX VENTURE: TBP) (OTCQB: TBPMF), a global leader in cannabinoid-based drug development and discovery, [...]
Ortho Regenerative Technologies Inc. Announces CFO Change
31/08/2018
KIRKLAND, Quebec, Aug. 31, 2018 (GLOBE NEWSWIRE) -- Ortho Regenerative Technologies Inc. ( CSE: ORTH ) (“ Ortho RTi ” or the “ Corporation” ) announces that Benedek (Ben) Simo has been appointed Interim Chief Financial [...]
Ascendis Pharma A/S Announces Upcoming Investor Presentations
31/08/2018
COPENHAGEN, Denmark, Aug. 31, 2018 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet medical needs, today [...]
LeMaitre Vascular to Present at Upcoming Investor Conferences
31/08/2018
BURLINGTON, Mass., Aug. 31, 2018 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will be presenting at the Wells Fargo Healthcare and RW Baird Healthcare conferences next week. George [...]
Exalenz Announces Second Quarter 2018 Financial Results
31/08/2018
Second quarter 2018 revenue increased 53% to $3.4 million, compared with $2.2 million in same period in 2017 The Company estimates total revenues for 2018 to reach $13 -14 million, an increase of 37 – 47% over 2017, and [...]
Olainfarm’s Six Months Net Profit Reaches 5,78 million euros
31/08/2018
Unaudited Consolidated Income Statement of AS Olainfarm for first six months of 2018 shows that the sales of the Group have reached 61.8 million euros, which represents a slight decrease of 1% compared to the same [...]
Oncology Venture A/S: Publication of financial report for January - June 2018
31/08/2018
Oncology Venture A/S ("Oncology Venture", formerly Medical Prognosis Institute A/S) hereby publishes the financial report for the period of January - June 2018. The report is available as an attached document to this [...]
Cytori Therapeutics to Present at the 20th Annual Rodman & Renshaw Global Investment Conference
31/08/2018
Presentation on Thursday, September 06, 2018 at 09:10 AM Eastern Time SAN DIEGO, Aug. 31, 2018 (GLOBE NEWSWIRE) -- Cytori Therapeutics, Inc. (NASDAQ: CYTX) announced today that it will present at the 20 th Annual Rodman [...]
Oncology Venture A/S establish a flexible loan facility of up to SEK 40 million
31/08/2018
Oncology Venture A/S ("Oncology Venture", formerly Medical Prognosis Institute A/S) hereby announces that the company has entered into a flexible loan agreement with Trention AB. Under the terms of the agreement, [...]
Genmab Announces European Marketing Authorization for DARZALEX® (daratumumab) for Front Line Multiple Myeloma
31/08/2018
Company Announcement DARZALEX approved in Europe in combination with bortezomib, melphalan and prednisone in patients with newly diagnosed multiple myeloma Approval follows positive opinion by European Committee for [...]
Zynerba Pharmaceuticals to Present at the H.C. Wainwright 20th Annual Global Investment Conference
31/08/2018
DEVON, Pa., Aug. 31, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric [...]
Portola Pharmaceuticals Submits Prior Approval Supplement to U.S. FDA for Large-Scale Generation 2 Andexxa Process
31/08/2018
SOUTH SAN FRANCISCO, Calif., Aug. 31, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. ® (Nasdaq:PTLA) today announced the submission of a prior approval supplement (PAS) to the U.S. Food and Drug Administration ( [...]
Selecta Biosciences Announces Presentation at the 20th Asia Pacific League of Associations for Rheumatology Congress (APLAR)
31/08/2018
WATERTOWN, Mass., Aug. 31, 2018 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq: SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies by mitigating [...]
Rubius Therapeutics Reports Second Quarter 2018 Financial Results
31/08/2018
CAMBRIDGE, Mass., Aug. 31, 2018 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a biotechnology company pioneering the development of a new class of ready-to-use cellular therapies, today reported second [...]
Altimmune Announces Initial Single-Dose Data from Its NasoShield Phase 1 Study
31/08/2018
Studies funded by BARDA GAITHERSBURG, Md., Aug. 31, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced initial data from its Phase 1 study of NasoShield [...]
Atara Biotherapeutics to Participate at Two Upcoming Conferences
31/08/2018
SOUTH SAN FRANCISCO, Calif., Aug. 31, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with [...]
GUERBET : Nombre d'actions et de droits de vote composant le capital de la société au 31 juillet 2018
31/08/2018
Communiqué de presse Villepinte, le 31 août 2018 DECLARATION RELATIVE AU NOMBRE DE DROITS DE VOTE ET D'ACTIONS COMPOSANT LE CAPITAL DE LA SOCIETE En application de l'article L. 233-8 II du code de commerce et de l' [...]
Myriad Genetics to Present at the 2018 Morgan Stanley Global Healthcare Conference
31/08/2018
SALT LAKE CITY, Aug. 31, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and personalized medicine, announced today that Mark C. Capone, president and CEO, is scheduled [...]
Midatech Announces Interim Results from Proof of Concept Exploratory Study for its MTD201 Q-Octreotide Programme and Q-Sphera™ Microsphere Technology
31/08/2018
31 August 2018 Midatech Pharma PLC ("Midatech" or the "Company") Midatech Announces Interim Results from Proof of Concept Exploratory Study for its MTD201 Q-Octreotide Programme and Q-Sphera™ Microsphere Technology [...]

Pages